REATA PHARMACEUTICALS INC — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/509e5a79-2bd4-41f0-a247-f0d7e4d04243/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2022 | $2.2M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-004236 |
| FY 2021 | $11.5M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-007338 |
| FY 2020 | $9.0M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-009624 |
| FY 2019 | $26.5M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-005272 |
| FY 2018 | $53.6M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005161 |
| FY 2017 | $48.1M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-005161 |
| FY 2016 | $49.9M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-005161 |
| FY 2015 | $50.3M | 2015-01-01 – 2015-12-31 | evidence 0001564590-17-003245 |
| FY 2014 | $52.0M | 2014-01-01 – 2014-12-31 | evidence 0001564590-17-003245 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).